ArticleEukaryotic cell2008
Contribution of galactofuranose to the virulence of the opportunistic pathogen Aspergillus fumigatus.
Article in Eukaryotic cell, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 163 citations in OpenAlex.
- Integrative perspectives on glycosylation networks in fungi and oomycetes.Journal of microbiology (Seoul, Korea) · 2025Review
- Reverse Anomeric Effects in Pyranose and Furanose Isomers in Schiff Bases of d-Galactosamine.The Journal of organic chemistry · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Crystal structure of β-d-galactofuranosidase from Streptomyces sp. JHA19 in complex with an inhibitor provides insights into substrate specificity.FEBS letters · 2024Article
- Substrate binding and catalytic mechanism of UDP-α-D-galactofuranose: β-galactofuranoside β-(1→5)-galactofuranosyltransferase GfsA.PNAS nexus · 2024Article
- Intact cell lipidomics using the Bruker MBT lipid Xtract assay allows the rapid detection of glycosyl-inositol-phospho-ceramides fromMolecular omics · 2024Article
- Sirtuin E deacetylase is required for full virulence of Aspergillus fumigatus.Communications biology · 2024Article
- The postbiotic potential ofFrontiers in microbiology · 2024Review
- Pathogenicity and virulence ofVirulence · 2023Review
- Article
- Proteomics ofJournal of fungi (Basel, Switzerland) · 2023Article
- The Novel Monoclonal IgGJournal of fungi (Basel, Switzerland) · 2023Article
- Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host.Pathogens (Basel, Switzerland) · 2023Review
- Complement, but Not Platelets, Plays a Pivotal Role in the Outcome of Mucormycosis In Vivo.Journal of fungi (Basel, Switzerland) · 2023Article
- Identification of Compounds PreventingInternational journal of molecular sciences · 2023Article
- Identification of galactofuranose antigens such as galactomannoproteins and fungal-type galactomannan from the yellowFrontiers in microbiology · 2023Article
- Assessing Differences between Clinical Isolates ofPathogens (Basel, Switzerland) · 2022Article
- Role of Protein Glycosylation in Interactions of Medically Relevant Fungi with the Host.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The filamentous fungus Aspergillus fumigatus is responsible for a lethal disease called invasive aspergillosis that affects immunocompromised patients. This disease, like other human fungal diseases, is generally treated by compounds targeting the primary fungal cell membrane sterol. Recently, glucan synthesis inhibitors were added to the limited antifungal arsenal and encouraged the search for novel targets in cell wall biosynthesis. Although galactomannan is a major component of the A. fumigatus cell wall and extracellular matrix, the biosynthesis and role of galactomannan are currently unknown. By a targeted gene deletion approach, we demonstrate that UDP-galactopyranose mutase, a key enzyme of galactofuranose metabolism, controls the biosynthesis of galactomannan and galactofuranose containing glycoconjugates. The glfA deletion mutant generated in this study is devoid of galactofuranose and displays attenuated virulence in a low-dose mouse model of invasive aspergillosis that likely reflects the impaired growth of the mutant at mammalian body temperature. Furthermore, the absence of galactofuranose results in a thinner cell wall that correlates with an increased susceptibility to several antifungal agents. The UDP-galactopyranose mutase thus appears to be an appealing adjunct therapeutic target in combination with other drugs against A. fumigatus. Its absence from mammalian cells indeed offers a considerable advantage to achieve therapeutic selectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.